Online first
Original paper
Published online: 2024-12-11
Fibroblast growth factor 21 in patients with mild autonomic cortisol secretion and non-functioning adrenal incidentalomas
1
, 2, 3, 4
, 2, 3, 4
Abstract
Introduction: Epidemiological studies have reported a link between adrenocortical adenomas (ACA), obesity, and cardiometabolic risk. Fibroblast growth factor 21 (FGF21) is a stress-induced protein synthesised predominantly in the liver, which regulates metabolism. The aim of the current study was to evaluate the concentration of FGF21 in patients with ACA and its relationship with hypothalamic-pituitary-
adrenal function, obesity, markers of cardiometabolic health, and adenoma size.
Material and methods: A total of 197 patients with ACA were included in the analysis, 82 diagnosed with mild autonomous cortisol secretion (MACS) and 115 with non-functioning adrenal adenoma incidentaloma (NFAI). MACS was defined as serum cortisol concentration post 1 mg dexamethasone test (DST) ≥ 1.8 μg/dL. In each patient weight, height, and waist circumference were measured, and body mass index (BMI) was calculated. Serum concentrations of FGF21, cortisol, dehydroepiandrosterone sulphate, adrenocorticotropic hormone (ACTH), total cholesterol, high-density lipoprotein cholesterol (HDL-C), low density lipoprotein cholesterol (LDL-C), triglycerides, glucose, and insulin were measured. The cortisol-to ACTH ratio, homeostatic model assessment for insulin resistance index (HOMA-IR), lipid accumulation product (LAP), and cardiometabolic index (CMI) were calculated. Adrenal tumour size was evaluated from imaging procedures.
Results: Serum FGF21 concentrations were significantly higher in patients with MACS than in NFAI, which was independent of BMI. There were no differences between MACS and NFAI groups regarding HOMA-IR, LAP, and CMI. We observed a positive correlation between serum FGF21 concentration and cortisol level after DST, as well as the cortisol-to-ACTH ratio. FGF21 was negatively correlated with dehydroepiandrosterone sulphate (DHEAS). There were no significant correlations between serum FGF21 concentration and BMI, waist circumference, and HOMA-IR, but serum FGF21 levels were positively correlated with TG, LAP, and CMI. Positive relationships between adenoma size and serum FGF21 concentration were found.
Conclusions: Higher levels of FGF21 in adrenal tumours with MACS when compared with NFAI represent another pathophysiological link related to chronic glucocorticoid excess.
Keywords: FGF21adrenal incidentalomamild autonomic cortisol secretionadrenal adenoma sizecardiometabolic indexlipid accumulation productobesity
References
- Bancos I, Prete A. Approach to the Patient With Adrenal Incidentaloma. J Clin Endocrinol Metab. 2021; 106(11): 3331–3353.
- Prete A, Bancos I. Mild autonomous cortisol secretion: pathophysiology, comorbidities and management approaches. Nat Rev Endocrinol. 2024; 20(8): 460–473.
- Pelsma ICM, Fassnacht M, Tsagarakis S, et al. Comorbidities in mild autonomous cortisol secretion and the effect of treatment: systematic review and meta-analysis. Eur J Endocrinol. 2023; 189(4): S88–S8S101.
- Fassnacht M, Tsagarakis S, Terzolo M, et al. European Society of Endocrinology clinical practice guidelines on the management of adrenal incidentalomas, in collaboration with the European Network for the Study of Adrenal Tumors. Eur J Endocrinol. 2023; 189(1): G1–G42.
- Arruda M, Mello Ribeiro Cavalari E, Pessoa de Paula M, et al. The presence of nonfunctioning adrenal incidentalomas increases arterial hypertension frequency and severity, and is associated with cortisol levels after dexamethasone suppression test. J Hum Hypertens. 2017; 32(1): 3–11.
- Peppa M, Koliaki C, Raptis SA. Adrenal incidentalomas and cardiometabolic morbidity: an emerging association with serious clinical implications. J Intern Med. 2010; 268(6): 555–566.
- Podbregar A, Janez A, Goricar K, et al. The prevalence and characteristics of non-functioning and autonomous cortisol secreting adrenal incidentaloma after patients' stratification by body mass index and age. BMC Endocr Disord. 2020; 20(1): 118.
- Sydney GI, Ioakim KJ, Paschou SA. Insulin resistance and adrenal incidentalomas: A bidirectional relationship. Maturitas. 2019; 121: 1–6.
- Reincke M, Fassnacht M, Väth S, et al. Adrenal incidentalomas: a manifestation of the metabolic syndrome? Endocr Res. 1996; 22(4): 757–761.
- Altieri B, Tirabassi G, Della Casa S, et al. Adrenocortical tumors and insulin resistance: What is the first step? Int J Cancer. 2016; 138(12): 2785–2794.
- Muscogiuri G, Sorice GP, Prioletta A, et al. The size of adrenal incidentalomas correlates with insulin resistance. Is there a cause-effect relationship? Clin Endocrinol (Oxf). 2011; 74(3): 300–305.
- Midorikawa S, Sanada H, Hashimoto S, et al. The improvement of insulin resistance in patients with adrenal incidentaloma by surgical resection. Clin Endocrinol (Oxf). 2001; 54(6): 797–804.
- Gospodarowicz D, Ill CR, Hornsby PJ, et al. Control of bovine adrenal cortical cell proliferation by fibroblast growth factor. Lack of effect of epidermal growth factor. Endocrinology. 1977; 100(4): 1080–1089.
- Hornsby PJ, Gill GN. Hormonal control of adrenocortical cell proliferation. Desensitization to ACTH and interaction between ACTH and fibroblast growth factor in bovine adrenocortical cell cultures. J Clin Invest. 1977; 60(2): 342–352.
- Lerario AM, Finco I, LaPensee C, et al. Molecular Mechanisms of Stem/Progenitor Cell Maintenance in the Adrenal Cortex. Front Endocrinol (Lausanne). 2017; 8: 52.
- Woo YuC, Lee CHo, Fong CHY, et al. Serum fibroblast growth factor 21 is a superior biomarker to other adipokines in predicting incident diabetes. Clin Endocrinol (Oxf). 2017; 86(1): 37–43.
- Liang Q, Zhong L, Zhang J, et al. FGF21 maintains glucose homeostasis by mediating the cross talk between liver and brain during prolonged fasting. Diabetes. 2014; 63(12): 4064–4075.
- Matuszek B, Lenart-Lipińska M, Duma D, et al. Evaluation of concentrations of FGF-21 - a new adipocytokine in type 2 diabetes. Endokrynol Pol. 2010; 61(1): 50–54.
- Szczepańska E, Gietka-Czernel M. FGF21: A Novel Regulator of Glucose and Lipid Metabolism and Whole-Body Energy Balance. Horm Metab Res. 2022; 54(4): 203–211.
- Vernia S, Cavanagh-Kyros J, Garcia-Haro L, et al. The PPARα-FGF21 hormone axis contributes to metabolic regulation by the hepatic JNK signaling pathway. Cell Metab. 2014; 20(3): 512–525.
- Kim H, Jung J, Park S, et al. Exercise-Induced Fibroblast Growth Factor-21: A Systematic Review and Meta-Analysis. Int J Mol Sci. 2023; 24(8).
- Dille M, Nikolic A, Wahlers N, et al. Long-term adjustment of hepatic lipid metabolism after chronic stress and the role of FGF21. Biochim Biophys Acta Mol Basis Dis. 2022; 1868(1): 166286.
- Bookout AL, de Groot MHM, Owen BM, et al. FGF21 regulates metabolism and circadian behavior by acting on the nervous system. Nat Med. 2013; 19(9): 1147–1152.
- Liang Q, Zhong L, Zhang J, et al. FGF21 maintains glucose homeostasis by mediating the cross talk between liver and brain during prolonged fasting. Diabetes. 2014; 63(12): 4064–4075.
- Larson KR, Jayakrishnan D, Soto Sauza KA, et al. FGF21 Induces Skeletal Muscle Atrophy and Increases Amino Acids in Female Mice: A Potential Role for Glucocorticoids. Endocrinology. 2024; 165(3).
- Patel R, Bookout AL, Magomedova L, et al. Glucocorticoids regulate the metabolic hormone FGF21 in a feed-forward loop. Mol Endocrinol. 2015; 29(2): 213–223.
- Ďurovcová V, Marek J, Hána V, et al. Plasma concentrations of fibroblast growth factors 21 and 19 in patients with Cushing's syndrome. Physiol Res. 2010; 59(3): 415–422.
- Ueland GÅ, Methlie P, Heie A, et al. Substantial changes in inflammatory and cardiovascular biomarkers in patients with autonomous cortisol secretion. Eur J Endocrinol. 2023; 189(1): 78–86.
- Karatas S, Hacioglu Y, Beysel S. Metabolic syndrome and Visceral Adiposity Index in non-functional adrenal adenomas. Arch Endocrinol Metab. 2023; 67(3): 323–329.
- Reimondo G, Castellano E, Grosso M, et al. Adrenal Incidentalomas are Tied to Increased Risk of Diabetes: Findings from a Prospective Study. J Clin Endocrinol Metab. 2020; 105(4).
- Cyranska-Chyrek E, Szczepanek-Parulska E, Olejarz M, et al. Malignancy Risk and Hormonal Activity of Adrenal Incidentalomas in a Large Cohort of Patients from a Single Tertiary Reference Center. Int J Environ Res Public Health. 2019; 16(10).
- Kiszczak-Bochyńska E, Oszywa A, Kurowska M, et al. Features of metabolic syndrome in patients with adrenal incidentalomas. Family Med. Primary Care Rev. 2014; 16(3): 242–244.
- Araujo-Castro M, Parra Ramírez P, Robles Lázaro C, et al. Predictors of Tumour Growth and Autonomous Cortisol Secretion Development during Follow-Up in Non-Functioning Adrenal Incidentalomas. J Clin Med. 2021; 10(23).
- Boutari C, Mantzoros CS. A 2022 update on the epidemiology of obesity and a call to action: as its twin COVID-19 pandemic appears to be receding, the obesity and dysmetabolism pandemic continues to rage on. Metabolism. 2022; 133: 155217.
- World Health Organization. World Health Statistics 2023: Monitoring Health for the SDGs, Sustainable Development Goals. World Health Organization, Geneva 2023.
- Szychlińska M, Rzeczkowska M, Matuszewski W, et al. Could a nonfunctional adrenal incidentaloma be a risk factor for increased carotid intima-media thickness and 10-year cardiovascular mortality based on the SCORE algorithm? A study from a single centre in Poland. Endokrynol Pol. 2023; 74(6).
- Morelli V, Reimondo G, Giordano R, et al. Long-term follow-up in adrenal incidentalomas: an Italian multicenter study. J Clin Endocrinol Metab. 2014; 99(3): 827–834.
- Elhassan YS, Alahdab F, Prete A, et al. Natural History of Adrenal Incidentalomas With and Without Mild Autonomous Cortisol Excess: A Systematic Review and Meta-analysis. Ann Intern Med. 2019; 171(2): 107–116.
- Boscaro M, Giacchetti G, Ronconi V. Visceral adipose tissue: emerging role of gluco- and mineralocorticoid hormones in the setting of cardiometabolic alterations. Ann N Y Acad Sci. 2012; 1264(1): 87–102.
- Jimeno B, Verhulst S. Meta-analysis reveals glucocorticoid levels reflect variation in metabolic rate, not 'stress'. Elife. 2023; 12.
- Kuckuck S, van der Valk ES, Scheurink AJW, et al. Glucocorticoids, stress and eating: The mediating role of appetite-regulating hormones. Obes Rev. 2023; 24(3): e13539.
- Ors D, Altinova AE, Yalçın M, et al. Fibroblast growth factor 21 and its relationship with insulin sensitıvity ın first-degree relatives of patients wıth type 2 dıabetes mellıtus. Endokrynol Pol. 2015.
- Solon-Biet SM, Clark X, Bell-Anderson K, et al. Toward reconciling the roles of FGF21 in protein appetite, sweet preference, and energy expenditure. Cell Rep. 2023; 42(12): 113536.
- Yu H, Xia F, Lam KSL, et al. Circadian rhythm of circulating fibroblast growth factor 21 is related to diurnal changes in fatty acids in humans. Clin Chem. 2011; 57(5): 691–700.
- Freedman MR, Horwitz BA, Stern JS. Effect of adrenalectomy and glucocorticoid replacement on development of obesity. Am J Physiol. 1986; 250(4 Pt 2): R595–R607.
- Xu J, Shao X, Zeng H, et al. Hepatic-Specific FGF21 Knockout Abrogates Ovariectomy-Induced Obesity by Reversing Corticosterone Production. Int J Mol Sci. 2023; 24(19).
- Iwamoto Y, Tatsumi F, Itoh T, et al. Usefulness of cortisol/ACTH ratio (CAR) for diagnosis of cushing's syndrome: comparison of CAR with findings in dexamethasone suppression test. Sci Rep. 2022; 12(1): 17680.
- Al-Aqil FA, Monte MJ, Peleteiro-Vigil A, et al. Interaction of glucocorticoids with FXR/FGF19/FGF21-mediated ileum-liver crosstalk. Biochim Biophys Acta Mol Basis Dis. 2018; 1864(9 Pt B): 2927–2937.
- Vispute SG, Bu P, Le Y, et al. Activation of GR but not PXR by dexamethasone attenuated acetaminophen hepatotoxicities via Fgf21 induction. Toxicology. 2017; 378: 95–106.
- Yang M, Liu C, Jiang Na, et al. Fibroblast growth factor 21 in metabolic syndrome. Front Endocrinol (Lausanne). 2023; 14: 1220426.
- Li S, Zou T, Chen J, et al. Fibroblast growth factor 21: An emerging pleiotropic regulator of lipid metabolism and the metabolic network. Genes Dis. 2024; 11(3): 101064.
- Zhang X, Yeung DCY, Karpisek M, et al. Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans. Diabetes. 2008; 57(5): 1246–1253.
- Hao L, Huang KH, Ito K, et al. Fibroblast Growth Factor 21 (Fgf21) Gene Expression Is Elevated in the Liver of Mice Fed a High-Carbohydrate Liquid Diet and Attenuated by a Lipid Emulsion but Is Not Upregulated in the Liver of Mice Fed a High-Fat Obesogenic Diet. J Nutr. 2016; 146(2): 184–190.
- Fisher FM, Chui PC, Antonellis PJ, et al. Obesity is a fibroblast growth factor 21 (FGF21)-resistant state. Diabetes. 2010; 59(11): 2781–2789.
- Tyynismaa H, Raivio T, Hakkarainen A, et al. Liver fat but not other adiposity measures influence circulating FGF21 levels in healthy young adult twins. J Clin Endocrinol Metab. 2011; 96(2): E351–E355.
- Crudele L, Garcia-Irigoyen O, Cariello M, et al. Total serum FGF-21 levels positively relate to visceral adiposity differently from its functional intact form. Front Endocrinol (Lausanne). 2023; 14: 1159127.
- Lee SAh, Jeong E, Kim EH, et al. Various oscillation patterns of serum fibroblast growth factor 21 concentrations in healthy volunteers. Diabetes Metab J. 2012; 36(1): 29–36.
- Díaz-Delfín J, Hondares E, Iglesias R, et al. TNF-α represses β-Klotho expression and impairs FGF21 action in adipose cells: involvement of JNK1 in the FGF21 pathway. Endocrinology. 2012; 153(9): 4238–4245.
- Morrice N, Mcilroy GD, Tammireddy SR, et al. Elevated Fibroblast growth factor 21 (FGF21) in obese, insulin resistant states is normalised by the synthetic retinoid Fenretinide in mice. Sci Rep. 2017; 7: 43782.
- Kuryłowicz A, Puzianowska-Kuźnicka M. Induction of Adipose Tissue Browning as a Strategy to Combat Obesity. Int J Mol Sci. 2020; 21(17).
- Hondares E, Iglesias R, Giralt A, et al. Thermogenic activation induces FGF21 expression and release in brown adipose tissue. J Biol Chem. 2011; 286(15): 12983–12990.
- Patrova J, Kjellman M, Wahrenberg H, et al. Increased mortality in patients with adrenal incidentalomas and autonomous cortisol secretion: a 13-year retrospective study from one center. Endocrine. 2017; 58(2): 267–275.
- Pelsma ICM, Fassnacht M, Tsagarakis S, et al. Comorbidities in mild autonomous cortisol secretion and the effect of treatment: systematic review and meta-analysis. Eur J Endocrinol. 2023; 189(4): S88–S8S101.
- Pan X, Shao Y, Wu F, et al. FGF21 Prevents Angiotensin II-Induced Hypertension and Vascular Dysfunction by Activation of ACE2/Angiotensin-(1-7) Axis in Mice. Cell Metab. 2018; 27(6): 1323–1337.e5.
- Sbiera I, Kircher S, Altieri B, et al. Role of FGF Receptors and Their Pathways in Adrenocortical Tumors and Possible Therapeutic Implications. Front Endocrinol (Lausanne). 2021; 12: 795116.
- Tamburello M, Altieri B, Sbiera I, et al. FGF/FGFR signaling in adrenocortical development and tumorigenesis: novel potential therapeutic targets in adrenocortical carcinoma. Endocrine. 2022; 77(3): 411–418.
- Florea A, Harris RB, Klimentidis YC, et al. Circulating Fibroblast Growth Factor-21 and Risk of Metachronous Colorectal Adenoma. J Gastrointest Cancer. 2021; 52(3): 940–946.
- Kang YE, Kim JT, Lim MiAe, et al. Association between Circulating Fibroblast Growth Factor 21 and Aggressiveness in Thyroid Cancer. Cancers (Basel). 2019; 11(8).
- Cymbaluk-Płoska A, Gargulińska P, Chudecka-Głaz A, et al. The Suitability of FGF21 and FGF23 as New Biomarkers in Endometrial Cancer Patients. Diagnostics (Basel). 2020; 10(6).
